Search Results

You are looking at 1 - 10 of 14 items for :

  • "sunitinib" x
Clear All
Open access

Kosmas Daskalakis, Marina Tsoli, Anna Angelousi, Evanthia Kassi, Krystallenia I Alexandraki, Denise Kolomodi, Gregory Kaltsas and Anna Koumarianou

). MTTs with the MTOR inhibitor everolimus and the receptor tyrosine kinase (RTK) inhibitor sunitinib have been approved in clinical practice for locally advanced and metastatic pancreatic NENs (PanNENs) ( 2 , 3 ). In addition, everolimus has been shown

Open access

Giulia Bresciani, Angeliki Ditsiou, Chiara Cilibrasi, Viviana Vella, Federico Rea, Marco Schiavon, Narciso Giorgio Cavallesco, Georgios Giamas, Maria Chiara Zatelli and Teresa Gagliano

( 1 , 15 ). Everolimus and sunitinib are two targeted agents approved by the Food and Drugs Administration (FDA) for the treatment of different types of NENs ( 16 ). Everolimus is an mTOR inhibitor capable to slow down the tumour growth and arrest

Open access

Shan Wu, Jianjun Zhou, Jing Guo, Zhan Hua, Jianchen Li and Zai Wang

), particularly in liver metastasis ( 10 ). For this reason, sunitinib, a multi-targeted tyrosine kinase receptor inhibitor of VEGFR1-3, platelet-derived growth factor receptor, mast/stem cell growth factor receptor kit, proto-oncogene tyrosine-protein kinase

Open access

E T Aristizabal Prada and C J Auernhammer

disease of NETs of the GEP system ( 2 , 3 , 4 , 5 , 6 , 7 , 8 ), including molecular targeted therapy with the mammalian target of rapamycin (mTOR) inhibitor everolimus and the multi-tyrosinkinase inhibitor sunitinib, has significantly progressed

Open access

Anne Jouinot, Bernard Royer, Etienne Chatelut, Sotheara Moeung, Guillaume Assié, Audrey Thomas-Schoemann, Jérôme Bertherat, François Goldwasser and Benoit Blanchet

, in a phase II trial, efficacy and toxicity of sunitinib (0% of response and 26% of grade 3–4 adverse events) were lower than expected in ACC patients. Most of these patients received mitotane and were underexposed to sunitinib compared to the target

Open access

Xu Han, Xuefeng Xu, Hongyun Ma, Yuan Ji, Dansong Wang, Tiantao Kuang, Wenchuan Wu, Bin Song, Gang Li, Gang Jin and Wenhui Lou

patients had received hepatic arterial chemoembolization (HACE), four patients had received radiofrequency ablation (RFA), five patients had received Octreotide LAR, three patients had received sunitinib, one patient had received everolimus, seven patients

Open access

Qiuli Liu, Gang Yuan, Dali Tong, Gaolei Liu, Yuting Yi, Jun Zhang, Yao Zhang, Lin-ang Wang, Luofu Wang, Dianzheng Zhang, Rongrong Chen, Yanfang Guan, Xin Yi, Weihua Lan and Jun Jiang

years of age, she underwent pancreatic mass resection and pathological analysis of the mass showed a pancreatic NET. Considering her recurrent and multiple lesions, surgery was not considered suitable and therefore sunitinib was prescribed. A few months

Open access

Hanbaro Kim, Ki Byung Song, Dae Wook Hwang, Jae Hoon Lee, Shadi Alshammary and Song Cheol Kim

surgery. Adjuvant chemotherapy (including etoposide and cisplatin (EP) and capecitabine) and target therapy (including everolimus and sunitinib) were administered when recommended by oncologists. Follow-up Survival status was determined from

Open access

Anna Malczewska, Magdalena Witkowska, Karolina Makulik, Agnes Bocian, Agata Walter, Joanna Pilch-Kowalczyk, Wojciech Zajęcki, Lisa Bodei, Kjell Oberg and Beata Kos-Kudła

Sunitinib 1 – Previous treatments  Primary tumor resection 44 39 N/A Distal pancreatectomy: 32 RHC: 25 PancD (Traverso): 6 SBR: 14 PancD (Whipple): 2 – Enucleation: 3 – Partial pancreatectomy: 1

Open access

Joana Simões-Pereira, Daniel Macedo and Maria João Bugalho

these patients (case 19, Table 2 ) had been previously treated with tyrosine kinase inhibitors (TKIs) (7 months with sorafenib and 1 year with sunitinib) and CNS metastases developed under this treatment. Survival after CNS metastases’ diagnosis